Molecular Templates Inc (MTEM) concluded trading on Wednesday at a closing price of $0.34, with 2.79 million shares of worth about $0.95 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -74.10% during that period and on December 04, 2024 the price saw a loss of about -9.00%. Currently the company’s common shares owned by public are about 6.58M shares, out of which, 5.44M shares are available for trading.
Stock saw a price change of -9.00% in past 5 days and over the past one month there was a price change of -26.34%. Year-to-date (YTD), MTEM shares are showing a performance of -90.97% which decreased to -93.25% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.29 but also hit the highest price of $5.25 during that period. The average intraday trading volume for Molecular Templates Inc shares is 10.34 million. The stock is currently trading -13.60% below its 20-day simple moving average (SMA20), while that difference is down -52.47% for SMA50 and it goes to -77.11% lower than SMA200.
Molecular Templates Inc (NASDAQ: MTEM) currently have 6.58M outstanding shares and institutions hold larger chunk of about 41.02% of that.
The stock has a current market capitalization of $2.22M and its 3Y-monthly beta is at 1.08. It has posted earnings per share of -$2.70 in the same period. It has Quick Ratio of 1.56 while making debt-to-equity ratio of 1.55. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MTEM, volatility over the week remained 10.53% while standing at 27.00% over the month.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BofA Securities on April 21, 2021 offering a Buy rating for the stock and assigned a target price of $12 to it. Coverage by UBS stated Molecular Templates Inc (MTEM) stock as a Neutral in their note to investors on February 01, 2021, suggesting a price target of $13 for the stock. On September 08, 2020, Jefferies Initiated their recommendations, while on March 25, 2020, Stifel Initiated their ratings for the stock with a price target of $19. Stock get an Overweight rating from Barclays on February 27, 2020.
